Has anyone had the Signatera test after a breast cancer recurrence? My oncologist said a negative result would be...

Understanding the Signatera Test After Breast Cancer Recurrence

I can help you understand what this test means and what your oncologist's question really reflects about current medical practice. Let me address your three concerns systematically.

---

1) What the Signatera Test Is and What Results Mean

The Basic Concept:

The Signatera test is a liquid biopsy—a blood test that looks for circulating tumor DNA (ctDNA), which are tiny pieces of DNA from cancer cells floating in your bloodstream. According to the NCCN Guidelines for Metastatic Breast Cancer, liquid biopsies like this can detect "abnormal changes (mutations) that can be found by testing circulating tumor DNA (ctDNA) in the blood."

What Results Mean:

• Negative result: No detectable circulating tumor DNA in your blood. This may suggest your cancer is not actively progressing at this moment.
• Positive result: Detectable ctDNA is present, which may indicate cancer cells are present or active.

However—and this is important—a positive result doesn't automatically mean you need immediate treatment changes.

---

2) Why Your Oncologist Asked "What Are We Supposed to Do?"

Your oncologist's question reflects a real tension in modern cancer care. Here's what's happening:

The Clinical Reality:

According to expert discussions in Cancer Patient Lab webinars featuring breast cancer specialists, the Signatera test is still in what experts call the "promise stage" rather than standard clinical practice. One breast cancer physician (Dr. [removed] Lopez-Correa, MD, PhD) explained her own oncologist's initial hesitation:

"She said to me, bluntly and directly: 'I'm not going to change your treatment if this comes positive, so we're going to pay $6,000 for nothing because your treatment is going to be the same. We don't have any protocols right now that will indicate a change of treatment.'"

What This Means:

The test can detect circulating tumor DNA, but the medical field hasn't yet established clear, evidence-based protocols for what to do with that information. This is different from established tests like hormone receptor status or HER2 status, where positive/negative results directly guide treatment decisions.

However, there IS emerging clinical thinking:

According to the same expert discussion, doctors are beginning to use Signatera results in two ways:

1. Increased monitoring: A positive result might prompt more frequent imaging (CT scans, breast exams) to catch any recurrence earlier
2. Tumor burden tracking: The test provides a semi-quantitative measure—meaning it can show how much circulating tumor DNA is present. This allows doctors to track whether the tumor burden is stable, growing slowly, or changing rapidly

As one pathologist explained: "You can monitor it and say my volume doubling time of this undetectable tumor is one and a half years or two years. I watch it every year, and unless it really explodes, there's nothing I need to do."

---

3) What Medical Professionals Say About Using This Test

The Professional Consensus (Based on Current Guidelines):

According to NCCN Guidelines for Metastatic Breast Cancer, tumor mutation testing and biomarker testing are recommended, but the guidelines note that "testing is done using a variety of methods such as FISH, ISH, IHC, next-generation sequencing (NGS), and/or polymerase chain reaction (PCR)."

Signatera is a newer approach not yet fully integrated into standard NCCN recommendations.

What Oncologists Actually Do:

From Cancer Patient Lab expert discussions, here's how thoughtful oncologists are approaching this:

Dr. [removed] Apfel's perspective (pathologist/oncologist):

• A positive Signatera result doesn't automatically mean you must restart treatment
• It does mean you should increase vigilance with imaging
• It provides actionable information about your tumor burden trajectory
• The key question becomes: "Is my tumor burden stable, slowly growing, or rapidly accelerating?"

The Shared Decision-Making Approach:

According to NCCN Guidelines for Metastatic Breast Cancer, treatment decisions should involve "shared decision-making, where you and your team share information, discuss the options, and agree on a treatment plan."

This means:

• Your preferences matter
• Your goals of treatment matter (curative vs. palliative/comfort-focused)
• The test result is one piece of information, not the only factor

---

Key Questions to Ask Your Oncologist

Based on the medical literature and expert discussions, here are specific questions that would help clarify how your team would use this test:

1. "If the Signatera comes back positive, what would be your first step—more imaging, or would you consider treatment changes?"

2. "How would you use the semi-quantitative measure (the amount of ctDNA) to guide my monitoring plan?"

3. "What would constitute 'significant change' in the results that would prompt a treatment discussion?"

4. "Are there specific protocols or clinical trials at your center for patients with positive Signatera results?"

5. "How often would we repeat this test, and how would we coordinate it with my regular imaging?"

6. "What are your thoughts on using this test to increase monitoring frequency versus using it to guide treatment decisions?"

---

The Bottom Line: Current State of the Evidence

According to NCCN Guidelines and expert consensus:

✅ What we know:

• Signatera can detect circulating tumor DNA
• It provides information about tumor burden
• It may help guide monitoring intensity

❓ What's still being determined:

• Whether earlier detection of recurrence through this test actually improves survival outcomes
• What specific treatment protocols should follow a positive result
• How to standardize its use across different cancer centers

This is why your oncologist asked "What are we supposed to do?" — It's an honest acknowledgment that the test is useful for detection but the field is still developing clear action plans for positive results.

---

Important Context About Your Situation

According to NCCN Guidelines for Metastatic Breast Cancer, after initial treatment:

• You'll have regular monitoring including "physical exams, blood tests, imaging scans, and tumor testing (if needed)"
• "Monitoring is used to see if your cancer is responding to treatment, is stable, or is progressing"
• Your care team will assess "disease progression" based on imaging and physical exam

The Signatera test could become part of this monitoring strategy, but it's not yet the standard approach everywhere.

---

Summary of Evidence Coverage

| Topic | Evidence Strength | Source | |-------|-------------------|--------| | What Signatera detects | Strong | NCCN Guidelines; Expert webinars | | How results are interpreted | Strong | Expert consensus discussions | | Clinical protocols for positive results | Limited | Still emerging; not yet standardized | | How to use it for monitoring | Moderate | Expert discussions; not yet in NCCN guidelines | | Shared decision-making approach | Strong | NCCN Guidelines for Metastatic Breast Cancer |

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.

The most important conversation you can have is with your oncologist about their specific approach to using this test in your care plan—because right now, that's where the real clinical decision-making happens.